ME02670B - Antitela za MUC16 i metode za njihovu primenu - Google Patents

Antitela za MUC16 i metode za njihovu primenu

Info

Publication number
ME02670B
ME02670B MEP-2017-89A MEP8917A ME02670B ME 02670 B ME02670 B ME 02670B ME P8917 A MEP8917 A ME P8917A ME 02670 B ME02670 B ME 02670B
Authority
ME
Montenegro
Prior art keywords
antibody
antigen
binding fragment
cancer
subject
Prior art date
Application number
MEP-2017-89A
Other languages
German (de)
English (en)
French (fr)
Inventor
David Spriggs
Dharmarao Thapi
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of ME02670B publication Critical patent/ME02670B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (19)

1. Izolovana anititelo, ili nJegov antigen-vezujući fragment, koji se specifično vezuJe za MUC16 polipeptid ili za njegov antigenski deo, pri čemu je MUC16 polipeptid TLDRSSVLVDGYSPNRNE (identifikacioni broj u genskoj bazi:02) pri čemu antitelo sadrži varijabilni teški ("VH") lanac koji je kodiran sekvencom sa brojem :06 i varijabilni lak ("VL") lanac koji je kodiran sekvencom sa brojem 07.
2.Antitelo ili · njegov antigen-vezujući t'ragment prema patentnom' zahtevu l , pn čemu je antitelo monoklonsko antitelo.
3.Antitelo ili njegov antigen-vezujući fragment prema patentnom zahtevu l , pn čemu je antitelo himerno anititelo.
4.Humanizovano antitelo ili nJegov antigen-vezujući fragment koji je napravljen supstitucijom komplementarnih determini š ućih regiona antitela prema patentnom zahtevu l u humani okvirni domen, pri čemu humanizovano antitelo ili njegov antigen-vezujući fragment specifično vezuje MUC 16 polipeptid čija je sekvenca sa brojem:02 ili njegov antigenski deo.
5.Antitelo ili njegov antigen-vezujući fragment prema patentnom zahtevu 4, pri čemu su ostaci okvirnog domena zamenjeni sa odgovarajućim nehumanim ostacima.
6.Antitelo ili njegov antigen-vezujući fragment prema bilo kom od patentnih zahteva l do 5, pri čemu je antigen-vezujući fragment izabran iz grupe koja se sastoji od Fab fragmenta, F(ab')2 fragmenta, i Fv fragmenta .
7.Antitelo ili njegov antigen-vezujući fragment prema bilo kom od patentnih zahteva l do 6, pri čemu je antite lo, ili njegov antigen-vezujući fragment, kovalentno vezan za citotoksični agens ili prolek citotoksičnog agensa.
8.Antitelo ili antigen-vezujući fragment prema bi lo kom od patentnih zahteva l do 7, pri čemu je antitelo internalizovano u ćeliju.
9.Antitelo ili antigen-vezujući fragment prema bilo kom od patentnih zahteva l do 8, pri čemu antitelo ne pokazuje specifično vezivanje za glikozilovani MUCI6 ekstracelularni domen.
10.Kompozicija koja sadrži (a) antitelo, ili njegov antigen-vezujući fragment, prema bilo kom od patentnih zahteva l do 9, i (b) farmaceutski prihvatljivi nosač.
11.Hibridoma ćelija koja proizvodi antitelo, ili njegov antigen-vezujući fragment, prema patentnom zahtevu l .
12.Izolovana nukleotidna sekvenca koja sadrži polinukleotid koji kodira sekvencu varijabilnog teškog (VH) lanca i sekvencu varijabilnog lakog (VL) lanca antitela prema patentnom zahtevu l .
13.Antitelo prema bilo kom od patentnih zahteva 1-9 za primenu u metodi za identifikaciju subjekta koji ima karcinom pri čemu je MUC16 eksprimiran, pri čemu pomenuta metoda sadrži administraciju antitela subjektu i određivanje prisustva i lokacije antitela kod subjekta, pri čemu je antitelo radio-obeleženo.
14.Antitelo za primenu prema patentnom zahtevu 13, pri čemu je karcinom izabran iz grupe koja se sastoji od karcinoma ovarijuma i karcinoma dojke.
15.Ex vivo metoda za identifikaciju subjekta koji Ima karcinom kod koga je MUC 16 eksprimiran, pri čemu pomenuta metoda sadrži (a) kontaktiranje prvog uzorka iz subjekta sa antitelom prema bilo kom od patentnih zahteva 1-9 pod uslovima za specifično vezivanje antitela sa odgovarajućim antigenom; i (b) određivanje da li anti telo pokazuje povećani nivo vezivanja za prvi uzorak u poređenju sa kontrolnim uzorkom u kome nije prisutan karcinom kod koga je MUC 16 eksprimiran.
16.Ex vivo metoda prema patentnom zahtevu 15, pri čemu je karcinom izabran iz grupe koja se sastoji od karcinoma ovarijuma i karcinoma dojke.
17.Ex vivo metoda prema patentnom zahtevu 15 ili 16, pri čemu je određivanje izvedeno korišćenjem procedure koja je izabrana iz grupe koja se sastoji od imunohistohemije, enzimskog imunovezujućeg testa (ELISA), fluorescentno aktiviranog ćelijskog sortiranja (FACS), Western blata, imunoprecipitacije, i radiografije.
18.Antitelo ili njegov antigen-vezujući fragment prema bilo kom od patentnih zahteva 1-9 za primenu u lečenju karcinoma u kome je MUC 16 EP eksprimiran.
19.Antitelo ili njegov antigen-vezujući fragment za primenu prema patentnom zahtevu 18, pri čemu je karcinom .izabran iz grupe koja se sastoji od karcinoma ovarijuma i karcinoma dojke.
MEP-2017-89A 2010-03-26 2011-03-25 Antitela za MUC16 i metode za njihovu primenu ME02670B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31796410P 2010-03-26 2010-03-26
PCT/US2011/030025 WO2011119979A2 (en) 2010-03-26 2011-03-25 Antibodies to muc16 and methods of use thereof
EP11760326.6A EP2552959B1 (en) 2010-03-26 2011-03-25 Antibodies to muc16 and methods of use thereof

Publications (1)

Publication Number Publication Date
ME02670B true ME02670B (me) 2017-06-20

Family

ID=44673895

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-89A ME02670B (me) 2010-03-26 2011-03-25 Antitela za MUC16 i metode za njihovu primenu

Country Status (13)

Country Link
US (4) US9169328B2 (me)
EP (2) EP3222632A1 (me)
JP (8) JP5837567B2 (me)
AU (1) AU2011230590C1 (me)
CA (4) CA3002192C (me)
DK (1) DK2552959T3 (me)
ES (1) ES2621874T3 (me)
HK (1) HK1244496A1 (me)
HU (1) HUE032519T2 (me)
ME (1) ME02670B (me)
PL (1) PL2552959T3 (me)
PT (1) PT2552959T (me)
WO (1) WO2011119979A2 (me)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
WO2014160368A2 (en) * 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
CN106459990B (zh) * 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
EP3107567A4 (en) * 2014-02-19 2017-10-25 Cangene Corporation Methods of modulating an immune response
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
SG10202103475XA (en) * 2014-12-02 2021-05-28 Prospect Chartercare Rwmc Llc Methods and compositons for treating cancer
CN107667120B (zh) * 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
US11261232B2 (en) 2015-04-02 2022-03-01 Memorial Sloan Kettering Cancer Center TNFRSF14 / HVEM proteins and methods of use thereof
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3363814A4 (en) * 2015-10-14 2019-09-25 Nippon Zenyaku Kogyo Co., Ltd. CANINE ANTI-TARC ANTIBODY FOR THE TREATMENT AND DIAGNOSIS OF CANINE ATOPIC DERMATITIS
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MY194596A (en) * 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
ES2894731T3 (es) 2017-03-15 2022-02-15 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018200585A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
CN107557336B (zh) * 2017-09-15 2020-02-14 山东兴瑞生物科技有限公司 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
RU2747095C2 (ru) * 2018-05-11 2021-04-26 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125
US11319380B2 (en) 2018-06-04 2022-05-03 Precigen, Inc. MUC16 specific chimeric antigen receptors and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
BR112021001338A2 (pt) * 2018-07-26 2021-05-04 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo
JP2022500413A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド Ｔｏｌｌ様受容体アゴニストの抗体コンジュゲート
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
AU2019337654A1 (en) 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
US20210388317A1 (en) * 2018-10-26 2021-12-16 Shinshu University High-efficiency method for producing genetically modified cells
MX2021005751A (es) * 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020227538A1 (en) * 2019-05-08 2020-11-12 Memorial Sloan Kettering Cancer Center Humanized antibodies to mucin-16 and methods of use thereof
WO2021019706A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
WO2021030665A1 (en) 2019-08-15 2021-02-18 Silverback Therapeutics, Inc. Formulations of benzazepine conjugates and uses thereof
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
AU2021308078A1 (en) 2020-07-17 2023-02-09 Children's Hospital Los Angeles Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
JP2025525779A (ja) 2022-07-29 2025-08-07 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN119978126A (zh) * 2023-11-10 2025-05-13 深圳市菲鹏生物治疗股份有限公司 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用
TW202523694A (zh) * 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途
WO2025168802A1 (en) 2024-02-09 2025-08-14 Oslo Universitetssykehus Hf Chimeric antigen receptor binding to ca125 for treating ovarian cancer
CN119638843B (zh) * 2024-03-20 2025-08-26 武汉勖瑞生物科技有限责任公司 一种抗ca125蛋白的单克隆抗体及其应用
CN118791617B (zh) * 2024-07-02 2025-03-07 安徽德合功生物科技有限公司 Ca125单克隆抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US505713A (en) 1893-09-26 Thomas j
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
AU5554190A (en) 1989-05-08 1990-11-29 Mark I. Farber Process and apparatus for the recovery of precious metals from slag, tailings and other materials
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1995021381A1 (en) 1994-02-01 1995-08-10 The Rockefeller University Methods and agents for measuring and controlling multidrug resistance
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
US6905839B2 (en) 2002-07-31 2005-06-14 Takashi Furuta In vivo phenotyping for human cytochrome P450 3A activity
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
CN1981054A (zh) 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
NZ563370A (en) 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2144628B1 (en) * 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method
EP3019872A4 (en) 2013-07-09 2016-06-29 Univ Nebraska Novel method for targetting glycoproteins for the treatment of cancer
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用

Also Published As

Publication number Publication date
JP7100595B2 (ja) 2022-07-13
JP2020072681A (ja) 2020-05-14
US20130171152A1 (en) 2013-07-04
HUE032519T2 (en) 2017-09-28
US20210309758A1 (en) 2021-10-07
JP2024073610A (ja) 2024-05-29
CA3255551A1 (en) 2025-04-15
AU2011230590A2 (en) 2014-02-20
US20160168262A1 (en) 2016-06-16
HK1244496A1 (en) 2018-08-10
EP2552959A4 (en) 2013-08-14
JP2022088649A (ja) 2022-06-14
DK2552959T3 (en) 2017-05-01
PL2552959T3 (pl) 2017-08-31
JP2015025006A (ja) 2015-02-05
ES2621874T3 (es) 2017-07-05
CA3188287C (en) 2025-07-08
US9169328B2 (en) 2015-10-27
AU2011230590B2 (en) 2015-01-15
EP2552959A2 (en) 2013-02-06
CA3188287A1 (en) 2011-09-29
US20180230231A1 (en) 2018-08-16
AU2011230590A1 (en) 2012-10-11
JP5837567B2 (ja) 2015-12-24
US10759869B2 (en) 2020-09-01
CA3002192A1 (en) 2011-09-29
EP3222632A1 (en) 2017-09-27
US11834513B2 (en) 2023-12-05
CA3002192C (en) 2023-03-07
JP2018117634A (ja) 2018-08-02
WO2011119979A3 (en) 2012-04-05
JP2019116474A (ja) 2019-07-18
JP2013529061A (ja) 2013-07-18
CA2793753A1 (en) 2011-09-29
CA2793753C (en) 2018-06-05
EP2552959B1 (en) 2017-01-11
PT2552959T (pt) 2017-04-21
US9790283B2 (en) 2017-10-17
JP6463068B2 (ja) 2019-01-30
JP2016144468A (ja) 2016-08-12
AU2011230590C1 (en) 2016-09-15
WO2011119979A2 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
ME02670B (me) Antitela za MUC16 i metode za njihovu primenu
ES2656620T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
US8426562B2 (en) Methods and compositions for modulating tumor cell activity
TWI485161B (zh) 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
Kalscheuer et al. Discovery of HSPG2 (Perlecan) as a therapeutic target in triple negative breast cancer
RU2012126098A (ru) Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
JP2013517487A5 (me)
RU2014120757A (ru) Связывающие молекулы, специфичные по отношению к her3, и их применения
JP2017149720A5 (me)
CN110139874B (zh) 抗ceacam6抗体及其使用方法
EA200970393A1 (ru) Новые антитела к cd38 для лечения рака
JP2013511288A5 (me)
PE20090368A1 (es) Anticuerpos anti-igf
CA3161827A1 (en) Anti-lilrb1 antibody and uses thereof
CN105007941A (zh) 抗-lamp1抗体和抗体药物偶联物及其用途
Song et al. Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity
Cua et al. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448
CN113993902B (zh) 抗her2结合分子
JP2013533732A5 (me)
Kim et al. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies
Fukuhara et al. A novel immunotoxin reveals a new role for CD321 in endothelial cells
TWI822815B (zh) 抗-人類ｐｄ-ｌ１之抗體及其用途
Guilmain et al. CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth
Tan et al. Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer
US9206258B2 (en) Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same